BIENERTOVÁ VAŠKŮ, Julie, Petr BIENERT, Dalibor VALÍK and Anna VAŠKŮ. Melanocortin system in cancer-related cachexia. Central European Journal of Medicine. Warsaw: Versita, 2011, vol. 6, No 5, p. 550-557. ISSN 1895-1058. Available from: https://dx.doi.org/10.2478/s11536-011-0057-6.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Melanocortin system in cancer-related cachexia
Name in Czech Melanokortinový systém v kachexii spojené s nádorovým onemocněním
Authors BIENERTOVÁ VAŠKŮ, Julie (203 Czech Republic, guarantor, belonging to the institution), Petr BIENERT (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic) and Anna VAŠKŮ (203 Czech Republic, belonging to the institution).
Edition Central European Journal of Medicine, Warsaw, Versita, 2011, 1895-1058.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30202 Endocrinology and metabolism
Country of publisher Poland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.312
RIV identification code RIV/00216224:14110/11:00052653
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2478/s11536-011-0057-6
UT WoS 000293708800005
Keywords (in Czech) melanokortiny; agouti-related peptid; kachexie, nádorová onemocnění
Keywords in English melanocortins; agouti-related peptide; cachexia; cancer
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 5/12/2011 13:31.
Abstract
The melanocortin system plays a pivotal role in the regulation of appetite and energy balance. It was recognized to play an important role in the development of cancer-related cachexia, a debilitating condition characterized by progressive body wasting associated with anorexia, increased resting energy expediture and loss of fat as well as lean body mass that cannot be simply prevented or treated by adequate nutritional support. The recent advances in understanding of mechanisms underlying cancer-related cachexia led to consequent recognition of the melanocortin system as an important potential therapeutic target. Several molecules have been made available for animal experiments, including those with oral bioavailability, that act at various checkpoints of the melanocortin system and that might confer singificant benefits for the patients suffering from cancer-related cachexia. The application of melanocortin 4 receptor antagonists/agouti-related peptide agonists has been however restricted to animal models and more pharmacological data will be necessary to progress to clinical trials on humans. Still, pharmacological targeting of the melanocortin system seem to represent an elegant and promising way of treatment of cancer-related cachexia.
Abstract (in Czech)
Tato review poskytuje přehled o významu melanokortinové dráhy při vzniku nádorové kachexia a zabývá se také možnými důsledky pro léčbu pacienta s nádorovým onemocněním.
PrintDisplayed: 4/10/2024 07:34